Drug intelligence / Profile preview

OJP3101

Development stage: Preclinical
Lead developer: Oncocross

Overview

OJP3101 is an investigational drug candidate being developed by Oncocross Co., Ltd. in partnership with Oncocross Australia Pty Ltd. The candidate was identified using Oncocross's proprietary AI platforms, RAPTOR AI™ and ONCO-RAPTOR AI™, which are designed to accelerate drug discovery and development by analyzing transcriptomic data to identify new indications for existing drugs or to discover novel candidates. OJP3101 is currently in the IND-enabling (in vivo) stage of development. Although specific details regarding its active ingredient, modality, and molecular target are proprietary and remain confidential, the drug is being positioned for the treatment of metabolic and cardiovascular diseases.

Beyond the preview

Go deeper on OJP3101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OJP3101.

Explore the full profile